CN114606235B - Cyclic RNA SIRT5 and application thereof in diagnosis and treatment of non-alcoholic fatty liver disease - Google Patents
Cyclic RNA SIRT5 and application thereof in diagnosis and treatment of non-alcoholic fatty liver disease Download PDFInfo
- Publication number
- CN114606235B CN114606235B CN202210305595.6A CN202210305595A CN114606235B CN 114606235 B CN114606235 B CN 114606235B CN 202210305595 A CN202210305595 A CN 202210305595A CN 114606235 B CN114606235 B CN 114606235B
- Authority
- CN
- China
- Prior art keywords
- sirt5
- nafld
- circrna
- liver
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101000616727 Homo sapiens NAD-dependent protein deacylase sirtuin-5, mitochondrial Proteins 0.000 title claims abstract description 110
- 102100021839 NAD-dependent protein deacylase sirtuin-5, mitochondrial Human genes 0.000 title claims abstract description 110
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title claims abstract description 94
- 238000011282 treatment Methods 0.000 title claims abstract description 12
- 238000003745 diagnosis Methods 0.000 title claims abstract description 7
- 125000004122 cyclic group Chemical group 0.000 title claims description 4
- 108091028075 Circular RNA Proteins 0.000 claims abstract description 16
- 230000014509 gene expression Effects 0.000 claims description 51
- 108091069088 Homo sapiens miR-150 stem-loop Proteins 0.000 claims description 17
- 239000013604 expression vector Substances 0.000 claims description 13
- 238000003259 recombinant expression Methods 0.000 claims description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 6
- 230000001965 increasing effect Effects 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 4
- 238000012544 monitoring process Methods 0.000 claims description 3
- 239000013598 vector Substances 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- -1 kit Substances 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000011161 development Methods 0.000 abstract description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 11
- 230000007246 mechanism Effects 0.000 abstract description 7
- 230000009286 beneficial effect Effects 0.000 abstract description 5
- 230000008506 pathogenesis Effects 0.000 abstract description 5
- 230000009471 action Effects 0.000 abstract description 4
- 229940121657 clinical drug Drugs 0.000 abstract description 3
- 238000012827 research and development Methods 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 34
- 210000005228 liver tissue Anatomy 0.000 description 30
- 230000002438 mitochondrial effect Effects 0.000 description 24
- 230000002503 metabolic effect Effects 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 19
- 210000003470 mitochondria Anatomy 0.000 description 19
- 230000018109 developmental process Effects 0.000 description 18
- 210000004185 liver Anatomy 0.000 description 18
- 238000000034 method Methods 0.000 description 17
- 230000013632 homeostatic process Effects 0.000 description 16
- 231100000240 steatosis hepatitis Toxicity 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 15
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 14
- 239000003642 reactive oxygen metabolite Substances 0.000 description 12
- 238000011160 research Methods 0.000 description 11
- 206010019708 Hepatic steatosis Diseases 0.000 description 10
- 208000004930 Fatty Liver Diseases 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 208000010706 fatty liver disease Diseases 0.000 description 9
- 230000000512 lipotoxic effect Effects 0.000 description 9
- 230000006677 mitochondrial metabolism Effects 0.000 description 9
- 102000011990 Sirtuin Human genes 0.000 description 8
- 108050002485 Sirtuin Proteins 0.000 description 8
- 230000035508 accumulation Effects 0.000 description 8
- 238000009825 accumulation Methods 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 230000007863 steatosis Effects 0.000 description 8
- 235000021314 Palmitic acid Nutrition 0.000 description 7
- 102000008221 Superoxide Dismutase-1 Human genes 0.000 description 7
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 210000003494 hepatocyte Anatomy 0.000 description 7
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 7
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 7
- 238000007254 oxidation reaction Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 102000018653 Long-Chain Acyl-CoA Dehydrogenase Human genes 0.000 description 6
- 108010027062 Long-Chain Acyl-CoA Dehydrogenase Proteins 0.000 description 6
- 208000019425 cirrhosis of liver Diseases 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 210000005229 liver cell Anatomy 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 230000002018 overexpression Effects 0.000 description 6
- 102100040515 Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial Human genes 0.000 description 5
- 241001559542 Hippocampus hippocampus Species 0.000 description 5
- 101000966982 Homo sapiens Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 238000013232 NAFLD rodent model Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000010874 in vitro model Methods 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 235000009200 high fat diet Nutrition 0.000 description 4
- 208000019423 liver disease Diseases 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 238000010306 acid treatment Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000010200 validation analysis Methods 0.000 description 3
- 102100022890 ATP synthase subunit beta, mitochondrial Human genes 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 101000903027 Homo sapiens ATP synthase subunit beta, mitochondrial Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 108020005196 Mitochondrial DNA Proteins 0.000 description 2
- 108010067028 Mitochondrial Permeability Transition Pore Proteins 0.000 description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 108700020471 RNA-Binding Proteins Proteins 0.000 description 2
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 2
- 108090000638 Ribonuclease R Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 230000006718 epigenetic regulation Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000006759 inflammatory activation Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000006372 lipid accumulation Effects 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 150000004668 long chain fatty acids Chemical class 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 230000006676 mitochondrial damage Effects 0.000 description 2
- 208000012268 mitochondrial disease Diseases 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- MNULEGDCPYONBU-WMBHJXFZSA-N (1r,4s,5e,5'r,6'r,7e,10s,11r,12s,14r,15s,16s,18r,19s,20r,21e,25s,26r,27s,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trio Polymers O([C@@H]1CC[C@@H](/C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)O[C@H]([C@H]2C)[C@H]1C)CC)[C@]12CC[C@@H](C)[C@@H](C[C@H](C)O)O1 MNULEGDCPYONBU-WMBHJXFZSA-N 0.000 description 1
- MNULEGDCPYONBU-DJRUDOHVSA-N (1s,4r,5z,5'r,6'r,7e,10s,11r,12s,14r,15s,18r,19r,20s,21e,26r,27s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers O([C@H]1CC[C@H](\C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)C(C)C(=O)[C@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)OC([C@H]2C)C1C)CC)[C@]12CC[C@@H](C)[C@@H](CC(C)O)O1 MNULEGDCPYONBU-DJRUDOHVSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- MNULEGDCPYONBU-YNZHUHFTSA-N (4Z,18Z,20Z)-22-ethyl-7,11,14,15-tetrahydroxy-6'-(2-hydroxypropyl)-5',6,8,10,12,14,16,28,29-nonamethylspiro[2,26-dioxabicyclo[23.3.1]nonacosa-4,18,20-triene-27,2'-oxane]-3,9,13-trione Polymers CC1C(C2C)OC(=O)\C=C/C(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)C\C=C/C=C\C(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-YNZHUHFTSA-N 0.000 description 1
- MNULEGDCPYONBU-VVXVDZGXSA-N (5e,5'r,7e,10s,11r,12s,14s,15r,16r,18r,19s,20r,21e,26r,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers C([C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)OC([C@H]1C)[C@H]2C)\C=C\C=C\C(CC)CCC2OC21CC[C@@H](C)C(C[C@H](C)O)O2 MNULEGDCPYONBU-VVXVDZGXSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- MNULEGDCPYONBU-UHFFFAOYSA-N 4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers CC1C(C2C)OC(=O)C=CC(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)CC=CC=CC(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-UHFFFAOYSA-N 0.000 description 1
- 102100034088 40S ribosomal protein S4, X isoform Human genes 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 102000009062 ADP Ribose Transferases Human genes 0.000 description 1
- 108010049290 ADP Ribose Transferases Proteins 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 1
- 229930182536 Antimycin Natural products 0.000 description 1
- BMZRVOVNUMQTIN-UHFFFAOYSA-N Carbonyl Cyanide para-Trifluoromethoxyphenylhydrazone Chemical compound FC(F)(F)OC1=CC=C(NN=C(C#N)C#N)C=C1 BMZRVOVNUMQTIN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 101000732165 Homo sapiens 40S ribosomal protein S4, X isoform Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100031455 NAD-dependent protein deacetylase sirtuin-1 Human genes 0.000 description 1
- 102100030710 NAD-dependent protein deacetylase sirtuin-3, mitochondrial Human genes 0.000 description 1
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 102100034943 Peptidyl-prolyl cis-trans isomerase F, mitochondrial Human genes 0.000 description 1
- 101710191011 Peptidyl-prolyl cis-trans isomerase F, mitochondrial Proteins 0.000 description 1
- 108091005770 SIRT3 Proteins 0.000 description 1
- 108010041191 Sirtuin 1 Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- CQIUKKVOEOPUDV-IYSWYEEDSA-N antimycin Chemical compound OC1=C(C(O)=O)C(=O)C(C)=C2[C@H](C)[C@@H](C)OC=C21 CQIUKKVOEOPUDV-IYSWYEEDSA-N 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000007622 bioinformatic analysis Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037237 body shape Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000008809 cell oxidative stress Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 230000007866 hepatic necrosis Effects 0.000 description 1
- 210000004024 hepatic stellate cell Anatomy 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 231100000437 hepatocellular injury Toxicity 0.000 description 1
- DLINORNFHVEIFE-UHFFFAOYSA-N hydrogen peroxide;zinc Chemical compound [Zn].OO DLINORNFHVEIFE-UHFFFAOYSA-N 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000005550 inflammation mediator Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000031142 liver development Effects 0.000 description 1
- 210000002311 liver mitochondria Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 230000006540 mitochondrial respiration Effects 0.000 description 1
- 230000021125 mitochondrion degradation Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229930191479 oligomycin Natural products 0.000 description 1
- MNULEGDCPYONBU-AWJDAWNUSA-N oligomycin A Polymers O([C@H]1CC[C@H](/C=C/C=C/C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)O[C@@H]([C@@H]2C)[C@@H]1C)CC)[C@@]12CC[C@H](C)[C@H](C[C@@H](C)O)O1 MNULEGDCPYONBU-AWJDAWNUSA-N 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000030028 protein demalonylation Effects 0.000 description 1
- 230000030428 protein desuccinylation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000006950 reactive oxygen species formation Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 229940080817 rotenone Drugs 0.000 description 1
- JUVIOZPCNVVQFO-UHFFFAOYSA-N rotenone Natural products O1C2=C3CC(C(C)=C)OC3=CC=C2C(=O)C2C1COC1=C2C=C(OC)C(OC)=C1 JUVIOZPCNVVQFO-UHFFFAOYSA-N 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000014745 severe cutaneous adverse reaction Diseases 0.000 description 1
- 101150045247 sirt5 gene Proteins 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/532—Closed or circular
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention relates to a circular RNA SIRT5 and application thereof in diagnosis and treatment of non-alcoholic fatty liver diseases. The invention discloses the action and mechanism of c i rcRNA SIRT5 in the occurrence and development of NAFLD, provides theoretical basis for enriching the pathogenesis and clinical treatment of NAFLD, and is beneficial to the development of molecular markers of NAFLD diseases and the research and development of clinical drugs.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to a circular RNA SIRT5 and application thereof in diagnosis and treatment of non-alcoholic fatty liver diseases.
Background
With the improvement of economy, the improvement of living standard and life span of people and the change of living habits, the incidence rate of non-alcoholic fatty liver disease (NAFLD) is in a trend of rapid increase, NAFLD is expected to replace chronic viral hepatitis in the future, becomes the most important chronic liver disease, and seriously threatens the life health of people. At present, with the improvement of diagnostic level and the deepening of mechanism research, people have certain understanding on the generation and development of fatty liver, but at present, no effective targeted therapeutic medicine or means is applied to clinic at home and abroad for the treatment of NAFLD, so that clearing the generation mechanism of fatty liver and finding effective prevention and treatment measures are still important subjects facing people for a long time.
NAFLD is usually a component of Metabolic syndrome, the manifestation of Metabolic syndrome in the liver, whereby scholars from 22 different countries of the world, including chinese scholars, agree that NAFLD is suggested to be renamed to Metabolic-disorder-associated fatty liver disease (MAFLD). NAFLD is involved in a wide range of clinical conditions, from benign liver disease steatosis, characterized by fat accumulation in hepatocytes, to Nonalcoholic steatohepatitis (NASH), characterized by inflammation, hepatocellular injury and liver fibrosis, which can further progress to cirrhosis and hepatocellular carcinoma. Although it is now clear that excessive accumulation of fatty acids in the liver due to obesity is the main cause of fatty liver development, not all obese patients are clinically complicated with NAFLD, nor are all patients with NAFLD obese, a phenomenon that is more pronounced in asian populations; in addition, only about 20-30% of patients with simple fatty liver develop further NASH and hepatic necrosis after fatty acids accumulate in the liver. Furthermore, the relationship between the development of steatosis, inflammation and fibrosis, as well as the key clinical outcomes, appears to vary greatly between individuals. This suggests that excessive accumulation of liver lipids is merely an indication of what causes abnormal deposition of lipids in the liver? How does excessive accumulation of liver lipids in turn cause NAFLD to develop? These important issues remain to be further elucidated.
Mitochondria are key organelles in cells, not only provide energy for cells, but also are important places for generating free radicals in cells, and even participate in regulating and controlling apoptosis. Under physiological conditions, mitochondria in cells are in dynamic changes, including changes in the morphology and structure of mitochondria, mitosis, regeneration and fusion of mitochondria, and mitophagy. Mitochondria maintain metabolic homeostasis in the body through their own homeostasis. During the pathogenesis of NAFLD, mitochondria first deal with excessive lipid overload in hepatocytes by balancing NAD +/NADH redox status and increasing mitochondrial elongation. With the progress of the disease, the adaptability and flexibility of mitochondria are reduced, the generation of Reactive Oxygen Species (ROS) is increased, and further, oxidative damage of Mitochondrial DNA (mtDNA), mitochondrial structural abnormality (expressed as giant mitochondria, mitochondrial crest loss and Mitochondrial particle turbidity), imbalance phenomena of Mitochondrial metabolic homeostasis such as lipid peroxidation and the like are caused, and the disease process is worsened. It is thus seen that liver mitochondrial damage is not only an early initiating event of NAFLD, but is continuously aggravated as NAFLD progresses, and rather throughout the course of NAFLD, since NAFLD is a mitochondrial disease in view of both fatty acid beta-oxidation and oxidative stress affecting the development and progression of NAFLD occurring primarily in mitochondria, and even researchers have proposed that NAFLD is a mitochondrial disease, mitochondrial damage has been the focus of the field of research on the pathogenesis of NAFLD. If the dynamic equilibrium of mitochondria is disrupted, the function of mitochondria and even the survival of cells will be affected. Mitochondrial energy metabolism disorders are the major cause of cellular oxidative stress, manifested by the formation of ROS. Therefore, an imbalance in mitochondrial metabolic homeostasis may be the key factor affecting abnormal accumulation of liver lipids and development of NAFLD. What is again what causes an imbalance in mitochondrial metabolic homeostasis?
Circular RNAs (Circular RNAs) are newly discovered endogenous non-coding RNAs with closed loop structures, have the characteristics of stability, universality, conservation, tissue specificity and the like, and play an important role in gene expression regulation. The circRNAs are not influenced by RNA exonuclease, are more stable in expression and not easy to degrade, and are widely expressed in a eukaryotic cell transcriptome. It has been found that circRNAs are aberrantly expressed in a number of human diseases, including cancer, neurodegenerative changes, cardiovascular disease, and the like. Although a great amount of circRNAs have been identified at present, only a few of the circRNAs have been revealed to date, and the functions involved in the circRNAs are mainly focused on miRNA sponges, cis-regulation of parental genes, competitive binding of RNA-binding proteins (RBPs), and translation of short peptides.
In the field of NAFLD research, due to the limited clinical liver tissue specimen acquisition and other factors, most of the past researches are only limited to the establishment of an in vitro model of NAFLD by using palmitic acid or oleic acid to intervene a human hepatoma cell strain or a normal hepatoma cell strain, or to use a high-fat diet to induce a mouse NAFLD model, and then to perform in vitro research and discussion through means of sequencing, silencing and overexpression, and there are few research reports related to the expression spectrum of circRNAs in the liver tissue of a NAFLD patient and further to discuss potential molecular mechanisms and molecular targets. Recently we focused on a study published in CELL by the professor group Su Shicheng, university of mountains in 2020, suggesting that hsa _ circ _0089762 was found to be low expressed in hepatic tissue of NASH cirrhosis by extracting primary fibroblasts from human hepatic tissue and was named as the Steatohepatitis-associated circRNA ATP5B regulator (SCAR). Further phenotypic and mechanistic studies found that circRNA SCARs can bind directly to ATP5B of mPTP complex ATP synthase and block CypD interaction with mPTP in resting state, among others. The research firstly focuses on the expression condition of circRNAs in hepatic stellate cells of patients with NASH accompanied with liver cirrhosis, and further discloses an important molecular mechanism for the development of the NASH to the occurrence of hepatic fibrosis and liver cirrhosis. The development of NASH to liver cirrhosis belongs to a relatively late stage of the progression of NAFLD diseases, and the research on the action and mechanism of circRNAs in early NAFLD patients is reported in relevant documents at home and abroad at present, and corresponding molecular markers and medicines are also lacked.
Disclosure of Invention
The purpose of the present invention is to provide a cyclic RNA that can be used for diagnosis, treatment, or disease monitoring of non-alcoholic fatty liver disease.
The invention provides a circular RNA SIRT5, and the nucleotide sequence of the circular RNA SIRT5 is shown in SEQ ID NO. 1.
The invention also provides a DNA fragment, which codes the circular RNA SIRT5 and is shown as SEQ ID NO. 2.
The invention also provides a recombinant expression vector which contains the DNA segment.
In some embodiments, the recombinant expression vector is a lentiviral vector.
The invention also provides a host cell containing the recombinant expression vector.
In some embodiments, the host cell is a HepG2 cell.
The invention also provides application of the circular RNA SIRT5, the DNA segment, the recombinant expression vector or the host cell in preparation of products for diagnosing, treating or monitoring the non-alcoholic fatty liver disease.
In some embodiments, the product is a reagent, kit, medicament, or device.
The invention also provides a medicament for treating non-alcoholic fatty liver disease, which comprises the circular RNA SIRT5, a DNA segment, a recombinant expression vector or a host cell and medicinal auxiliary materials.
The invention also provides application of the circular RNA SIRT5, the DNA segment, the recombinant expression vector or the host cell in preparation of products for inhibiting expression of hsa-miR-150-5P or improving expression of SIRT5 protein.
The invention firstly proves the relevance of unbalanced mitochondrial metabolism steady state and the development of circRNA SIRT5 and NAFLD in normal liver and NAFLD liver tissue samples, and then observes the dynamic process of the circRNA SIRT5 for regulating and controlling unbalanced mitochondrial metabolism steady state in liver cells in a mouse NAFLD model, discusses whether the SIRT5 can be used as an epigenetic regulation target point for interfering the NAFLD process, and reasonably regulates and controls whether the expression of the circRNA SIRT5 in the liver cells is beneficial to maintaining the balance of the mitochondrial metabolism steady state, thereby improving the prognosis of NAFLD patients. The invention discloses the action and mechanism of circRNA SIRT5 in the occurrence and development of NAFLD, provides theoretical basis for enriching the pathogenesis and clinical treatment of NAFLD, and is beneficial to the development of molecular markers of NAFLD diseases and the research and development of clinical drugs.
Drawings
FIG. 1 is a schematic diagram of the involvement of circRNA SIRT5 in the generation and development of NAFLD according to one embodiment of the present invention;
FIG. 2 shows the results of the second generation sequencing and analysis of CIRCRNA in NAFLD patient liver tissue according to one embodiment of the present invention; wherein, A: human liver tissue HE staining; b: second generation sequencing heatmap of circRNA of human liver tissue; c: wien analysis; d: verifying the expression of the circRNAs in a differential manner; e: human liver tissue mitochondria ECAR; f: human liver tissue mitochondria OCR; g: and (5) verifying the circularity of RNA.
FIG. 3 shows the results of circRNA SIRT5 reduction of fat deposition, ROS and inflammatory factor release in liver tissue of NAFLD mice in accordance with one embodiment of the present invention; wherein A: detecting the ROS expression level in mouse liver tissue cells and mitochondria; b: the amount of inflammatory factor expressed in the plasma of the mouse; c: body shape of normal mouse and NAFLD mouse; d: gross appearance of mouse liver tissue and oil red staining to observe steatosis.
FIG. 4 is a graph showing the results of circRNA SIRT5 inhibition of fat deposition and inflammatory factor release in a HepG2 cell lipotoxicity model in accordance with an embodiment of the present invention; wherein, A: circRNA expression after palmitic acid treatment; b: circRNA expression after palmitic acid treatment; c: liver enzyme levels in cells after palmitic acid treatment; d: observing the influence of circRNA SIRT5 on the steatosis of PA-treated hepG2 cells under a light microscope; e: detecting the ROS expression quantity in hepG2 cells and mitochondria; f: intracellular SIRT5 mRNA expression levels.
FIG. 5 shows the results of the detection of the correlation between the potential mechanism of action of circRNA SIRT5 and the prediction of target spots in accordance with one embodiment of the present invention; wherein, A: expression level of has-miR-150-5P in human liver tissue; b: the expression level of has-miR-150-5P in mouse liver tissues; c: expression level of has-miR-150-5P in hepG2 cells; d: expression levels of SIRT5 in human liver tissue; e: (ii) the expression level of SIRT5 in mouse liver tissue; f: the level of SIRT5 expression in hepG2 cells; g: the circRNA SIRT5 and hsa-miR-150-5P predict the situation of the binding site.
FIG. 6 shows the results of the circRNA SIRT 5-regulated SIRT5 and its downstream signal pathway protein expression according to one embodiment of the present invention; wherein, A: expression of SIRT5, ECH1, VLCAD and SOD1 in mouse liver tissue; b: expression of SIRT5, ECH1, VLCAD, and SOD1 in hepG2 cells; .
Detailed Description
In order to more concisely and clearly show the technical scheme, the purpose and the advantages of the invention, the invention is further described in detail by combining the specific embodiment and the attached drawings. It is understood that one skilled in the art can, in view of the present disclosure, modify the process parameters appropriately to achieve this. It is specifically noted that all such substitutions and modifications will be apparent to those skilled in the art and are intended to be included herein. While the methods and applications of this invention have been described in terms of preferred embodiments, it will be apparent to those of ordinary skill in the art that variations and modifications in the methods and applications described herein, as well as other suitable variations and combinations, may be made to implement and use the techniques of this invention without departing from the spirit and scope of the invention.
The invention selects 5 cases of liver tissues of normal liver tissue, mild NAFLD (5-10% of large-vesicular steatosis), moderate NAFLD (30-60% of large-vesicular steatosis) and severe NAFLD (60% of large-vesicular steatosis) of human to carry out second-generation sequencing of circRNAs, and the result indicates that 10 circRNAs which are expressed in correlation with the severity of diseases exist along with the aggravation of the severity of lesions compared with normal liver, thereby indicating that the circRNAs possibly play an important role in the occurrence and development of NAFLD. Wherein the expression level of 3 circRNAs is reduced, and the expression level of 7 circRNAs is increased. Then, the related data are subjected to differential expression analysis, venn analysis, gene function analysis, signal path analysis and expression verification experiments, and we find that expression change amplitude of novel _ circ _0029917 in the 10 differential genes is the largest and the correlation with the severity of diseases is the strongest. We further analyzed the parent gene to find that novel _ circ _0029917 is derived from reverse splicing of exons of the SIRT5 gene, and for ease of understanding we named novel _ circ _0029917 as circRNA SIRT5.
Sirtuins are a class of Nicotinamide adenine dinucleotide (NAD +) dependent protein deacylases and/or ADP ribosyltransferases, comprising 7 members, SIRT1-SIRT7. Different Sirtuin members have different subcellular localization and function. SIRT1, 6 and 7 are mainly localized in the nucleus, and SIRT3, 4 and 5 are distributed in mitochondria. Sirtuins are currently known to regulate a variety of biological processes: DNA repair, gene expression, cell survival, metabolism, aging, and the like. In mitochondrial sirtuins, SIRT5 shows unique affinity for negatively charged acyl lysine modifications and carries out protein desuccinylation, demalonylation and deglutarylation reactions. SIRT5 is widely distributed in the body, and has the highest content in brain, heart, liver, kidney, muscle and testis. SIRT5 can maintain mitochondrial metabolism and cellular homeostasis by regulating biological processes such as glucose oxidation, ketone body formation, fatty acid oxidation, ammonia and ROS detoxification. SIRT5 knockouts result in β oxidation impairment and accumulation of medium and long chain acylcarnitines in the liver and muscle of mice. SIRT5 can directly combine and activate copper/zinc superoxide dismutase through polysuccinylation, thereby enhancing the ROS detoxification function mediated by SOD 1. SIRT5 knockdown or knocked-out cells show reduced NADPH and GSH levels, resulting in impaired ability to scavenge ROS and increased sensitivity to oxidative stress. The Sirtuins family has been a focus of research in the field of metabolic disease for a long time. In the field of NAFLD, studies have shown that SIRT5 can reduce hepatic steatosis by modulating the deacetylation of metabolic-related proteins in ob/ob mice. In addition, SIRT5 knockout can impair the mitochondrial medium-chain fatty acid oxidation ability of liver of high-fat-fed mice, and aggravate fatty liver. Thus, SIRT5 is believed to play an important role as a metabolic receptor protein in maintaining mitochondrial metabolic homeostasis in the development and progression of NAFLD. In addition, we also found that changes in SIRT5 protein expression in human liver tissue are closely related to hepatocyte fat accumulation and the progression of NAFLD. These studies show that: simple obesity and insulin resistance are not determinants of hepatocyte fat accumulation and NAFLD, and SIRT 5-mediated imbalance in mitochondrial metabolic homeostasis may play a more important role in the development and progression of NAFLD. What are the promoters and intrinsic kinetics of SIRT5 protein expression abnormalities? Whether circRNA SIRT5 formed by reverse splicing of SIRT5 plays an important role in this process?
To this end, we initially investigated the effect of circRNA SIRT5 on SIRT 5-mediated imbalance in mitochondrial metabolic homeostasis. Lentiviruses were overexpressed by synthesis of circRNA SIRT5 and transfected into HepG2 cells. In an in vitro lipotoxicity model established by using palmitic acid, we find that the over-expression of circRNA SIRT5 can obviously promote the beta-oxidation of long-chain fatty acid and inhibit the generation of mitochondrial ROS, thereby reducing the release of inflammatory factors and relieving the lipotoxicity of cells. We therefore speculate that circRNA SIRT5 may regulate the development of NAFLD by regulating hepatocyte mitochondrial metabolic homeostasis, but the specific mechanism by which it participates in regulating NAFLD is not clear. We further found by bioinformatic analysis that SIRT5 is targeted and regulated by hsa-miR-150-5p, and the binding site of hsa-miR-150-5p is just present on the circRNA SIRT5. We also found that although circRNA SIRT5 is less homologous between human and mouse, SIRT5 and hsa-miR-150-5p are highly conserved in sequence between human and mouse, plus previous studies have reported precedent intervention in mouse disease progression with human non-coding RNA, which lays a solid foundation for our subsequent in vivo model validation of the phenotype and function of circRNA SIRT5. Meanwhile, we also found that the expression of circRNA SIRT5 in human NAFLD liver tissues and a HepG2 in vitro lipotoxicity model is in negative correlation with hsa-miR-150-5p, and is in positive correlation with the expression of SIRT5. We further speculate that circRNA SIRT5 may be involved in generation, development and regulation of NAFLD by adsorbing hsa-miR-150-5p and then up-regulating the expression of SIRT5, as shown in FIG. 1.
In conclusion, the invention firstly proves whether the correlation of the unbalanced mitochondrial metabolism steady state and the generation and development of the circRNA SIRT5 and NAFLD exists in normal liver and NAFLD liver tissue samples, and then observes the dynamic process of the circRNA SIRT5 for regulating and controlling the unbalanced mitochondrial metabolism steady state in the liver cells in a mouse NAFLD model, discusses whether the SIRT5 can be used as an epigenetic regulation target for interfering the NAFLD process, reasonably regulates and controls whether the expression of the circRNA SIRT5 in the liver cells is beneficial to maintaining the balanced mitochondrial metabolism steady state, and further improves the prognosis of NAFLD patients. The invention discloses the action and mechanism of circRNA SIRT5 in the occurrence and development of NAFLD, provides theoretical basis for enriching the pathogenesis and clinical treatment of NAFLD, and is beneficial to the development of molecular markers of NAFLD diseases and the research and development of clinical drugs.
circRNA SIRT5 sequence:
UAAAUGGAAAUGUUUUCUAACAUAUAAAAACCUACAGAAGAAGAAAAUAAUUUUCUGGAUCAAAUUAGAAGUCUGUAUUAUAUUGAUGUCUCCAGAUUCAAAUAUAUUAGAAAGCAGCCGUGGAGACAACCAUCUUCAUUUUGGGAGAAAUAACUAAAGUAGCUUAUUUAAAACUCGAUGUACCUCUUGUGGAGUUGUGGCUGAGAAUUACAAGAGUCCAAUUUGUCCAGCUUUAUCAGGAAAAGGGCUCCAGAACCUGGAACUCAAGAUGCCAGCAUCCCAGUUGAGAAACUUCCCCG
circRNA SIRT5 cDNA Gene sequence:
TAAATGGAAATGTTTTCTAACATATAAAAACCTACAGAAGAAGAAAATAATTTTCTGGATCAAATTAGAAGTCTGTATTATATTGATGTCTCCAGATTCAAATATATTAGAAAGCAGCCGTGGAGACAACCATCTTCATTTTGGGAGAAATAACTAAAGTAGCTTATTTAAAACTCGATGTACCTCTTGTGGAGTTGTGGCTGAGAATTACAAGAGTCCAATTTGTCCAGCTTTATCAGGAAAAGGGCTCCAGAACCTGGAACTCAAGATGCCAGCATCCCAGTTGAGAAACTTCCCCG
the specific research method is as follows:
1. analyzing the correlation of circRNA SIRT5, hsa-miR-150-5p and mitochondrial metabolic homeostasis related protein in liver tissues of NAFLD patients and healthy people
a. And (3) determination of biochemical indexes: cytokines (IL-1. Beta., TNF-. Alpha., IL-6, etc.) in peripheral blood or liver tissue reflect inflammatory activation states; detecting liver function indicators (ALT, AST);
detection of relevant indexes of NAFLD: the liver lipid aggregation and the morphological change are observed by using oil red O, HE for staining; mRNA and protein levels of liver tissue inflammation mediators (TNF-alpha, IL-1 and IL-6) are detected and detected by using a qRT-PCR (quantitative reverse transcription-polymerase chain reaction), western Blotting or immunohistochemical method;
c. detecting related indexes of mitochondrial metabolism steady state: seahorse detects the metabolic phenotype of liver mitochondria; detecting SOD1, ECH1, VLCAD and SIRT5 by Western Blotting; detecting ROS in cytoplasm and mitochondria respectively by a DCFH-DA method and a mitoSOX method; detecting the energy metabolism change of the mitochondria of the liver cells by using Seahorse;
expression and localization of circrna SIRT5 in liver tissues of NAFLD patients: detecting the expression of circRNA SIRT5 by methods such as qRT-PCR and the like; rnaseR digestion tolerance experiment verifies the cyclization condition of circRNA SIRT5; and analyzing the correlation among the circRNA SIRT5, the hsa-miR-150-5p and related indexes of mitochondrial metabolic stability by combining the indexes;
2. validation of the role of circRNA SIRT5 in the NAFLD mouse model
a. Constructing an animal model: NAFLD mouse models were established by feeding wild type C57BL/6J mice with a High-fat diet (HFD), and CD-fed wild type C57BL/6J mice were used as a control group. AAV8 liver specific virus vector transfection to establish mouse circRNA SIRT5 overexpression model;
b. biochemical detection: animal blood was drawn before the experiment, 1,8 weeks, 16 weeks after the start of the experiment. Reflecting the inflammatory activation state of the experimental animal by detecting serum cytokines (IL-1 beta, TNF alpha, IL-6 and the like); detecting liver function indicators (ALT, AST);
c. morphology of lipid accumulation by examination of the degree of hepatic steatosis on cryosections by oil red O staining;
d. detecting related indexes of mitochondrial metabolic homeostasis: detecting SOD1, ECH1, VLCAD and SIRT5 by Western Blotting; detecting ROS in cytoplasm and mitochondria respectively by a DCFH-DA method and a mitoSOX method;
expression and localization of circrna SIRT5 in liver tissue of NAFLD mice: qRT-PCR detects the expression levels of circRNA SIRT5, hsa-miR-150-5p and related indexes of mitochondrial metabolic homeostasis, and analyzes the correlation among the three indexes by combining the indexes;
3. validation of the role of circRNA SIRT5 in NAFLD hepatocyte in vitro models at the cellular level
NAFLD in vitro model construction: adopting palmitic acid to induce a HepG2 liver cell strain lipotoxicity model and circRNA SIRT5 overexpression lentivirus transfected cells so as to confirm the function of the circRNA SIRT5 in the NAFLD in-vitro model;
b. and (3) determination of biochemical indexes: liver function index and cytokine (IL-1 beta, TNF alpha, IL-6, etc.) in supernatant and cell homogenate;
d. morphology of lipid accumulation by oil red O staining to detect the degree of cell steatosis;
e. detecting related indexes of mitochondrial metabolism steady state: detecting SOD1, ECH1, VLCAD and SIRT5 by Western Blotting;
expression and identification of circrna SIRT5 in NAFLD in vitro model: qRT-PCR detects the expression level of the circRNA SIRT5, and analyzes the correlation among the circRNA SIRT5, hsa-miR-150-5p and related indexes of mitochondrial metabolic homeostasis by combining the indexes;
key technical description:
seahorse assay: to observe the association of altered mitochondrial function with NAFLD, we performed Seahorse assays on samples of liver tissue from patients with NAFLD and normal persons. The Seahorse XFp analyzer is an ideal tool for routine testing of metabolic phenotypes in vitro and in other limited samples, and is currently widely used in basic experimental research. We first performed linear purification using the sucrose method and these compounds (oligomycin, FCCP and a mixture of rotenone and antimycin a) were injected sequentially to measure ATP production, maximal respiration and non-mitochondrial respiration, respectively. The proton leak and basal respiratory volume are then calculated using these parameters and the basal breath.
The experimental results are as follows:
1. sequencing circRNAs on 5 samples of liver tissues of healthy people, NAFLD (5-10% of vesicular fatty liver), NAFLD (30-60% of vesicular fatty liver) and NAFLD (60% of vesicular fatty liver) respectively to obtain hundreds of potential pathogenic circRNAs. And (3) taking each group of NAFLD to perform difference analysis with healthy people respectively, then performing Venn analysis to search potential common pathogenic circRNAs, and the result indicates that 10 common difference circRNAs are found, wherein 3 common differences are low in expression, and 7 common differences are high in expression. Then, gene function analysis, signal path analysis and expression verification experiments are carried out on the 10 circRNAs, and we find that the variation range of novel _ circ _0029917 is the largest in the 10 different genes, and the correlation between the expression variation and the severity of diseases is the strongest. We further identified the circRNA SIRT5 cyclization property using RNase R digestion experiments, which suggested that circRNA SIRT5 is circular and resistant to RNase R digestion, see FIG. 2.
2. After constructing a wild type C57BL/6J mouse NAFLD model fed by high-fat diet and using circRNA SIRT5 to overexpress slow virus for transfection, the result indicates that the circRNA SIRT5 can obviously relieve the fatty lesion of mouse liver tissues, reduce the expression of mROS and cROS, and simultaneously can inhibit the release of hepatocyte inflammatory factors caused by NAFLD, and indicates that the circRNA SIRT5 can correct the mitochondrial metabolic homeostasis imbalance caused by NAFLD, which is shown in figure 3.
3. We synthesized circRNA SIRT5 overexpressing lentiviruses and transfected HepG2 cells. In the in vitro lipotoxicity model established by using palmitic acid, we find that overexpression of circRNA SIRT5 can significantly promote beta-oxidation of long-chain fatty acid and inhibit the generation of mitochondrial ROS, thereby reducing the release of inflammatory factors and relieving the lipotoxicity of cells, and see figure 4.
4. To investigate the potential mechanism of action of circRNA SIRT5, we analyzed whether it has protein coding potential by using three common protein potential prediction software, CPC, CNCI and PFAM, and the results suggest that the IRES score of circRNA SIRT5 is 0.728266 and none has protein translation potential. Further, the potential sites of mutual combination between circRNA/miR/mRNA are analyzed by using prediction software such as mirDB, target Scan, RNA Hydrid and the like, and the result shows that 3 sites capable of combining with hsa-miR-150-5p exist in the circRNA SIRT5, and the hsa-miR-150-5p can be combined with SIRT5 mRNA in a targeted mode. Subsequently, we found that the expression of hsa-miR-150-5P is increased and the mRNA expression of SIRT5 is reduced in human and mouse NAFLD liver tissues and HepG2 cell lipotoxicity models. In a HepG2 cell lipotoxicity model with circRNA SIRT5 over-expressed, the circRNA SIRT5 can obviously inhibit the expression of hsa-miR-150-5P and simultaneously can relieve the inhibition effect of hsa-miR-150-5P on SIRT5 mRNA, as shown in figure 5.
5. Subsequently, we observed the effect of circRNA SIRT5 on SIRT5 protein and related indicators of mitochondrial metabolic homeostasis in the mouse NAFLD model and HepG2 cytotoxicity model of circRNA SIRT5 overexpression. The results suggest that circRNA SIRT5 can up-regulate SIRT5 protein expression in mouse liver and HepG2 cells, and further up-regulate the expression of mitochondrial metabolic homeostasis-related proteins (ECH 1, VLCAD and SOD 1) downstream of the signaling pathway, as shown in fig. 6.
The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the scope of the invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention. Therefore, the protection scope of the present patent shall be subject to the appended claims.
Sequence listing
<110> Sichuan university Hospital in western China
<120> circular RNA SIRT5 and application thereof in diagnosis and treatment of non-alcoholic fatty liver disease
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 299
<212> RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 1
uaaauggaaa uguuuucuaa cauauaaaaa ccuacagaag aagaaaauaa uuuucuggau 60
caaauuagaa gucuguauua uauugauguc uccagauuca aauauauuag aaagcagccg 120
uggagacaac caucuucauu uugggagaaa uaacuaaagu agcuuauuua aaacucgaug 180
uaccucuugu ggaguugugg cugagaauua caagagucca auuuguccag cuuuaucagg 240
aaaagggcuc cagaaccugg aacucaagau gccagcaucc caguugagaa acuuccccg 299
<210> 2
<211> 299
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 2
taaatggaaa tgttttctaa catataaaaa cctacagaag aagaaaataa ttttctggat 60
caaattagaa gtctgtatta tattgatgtc tccagattca aatatattag aaagcagccg 120
tggagacaac catcttcatt ttgggagaaa taactaaagt agcttattta aaactcgatg 180
tacctcttgt ggagttgtgg ctgagaatta caagagtcca atttgtccag ctttatcagg 240
aaaagggctc cagaacctgg aactcaagat gccagcatcc cagttgagaa acttccccg 299
Claims (10)
1. A circular RNA SIRT5, characterized in that the nucleotide sequence of the circular RNA SIRT5 is shown as SEQ ID NO. 1.
2. A DNA fragment encoding the circular RNA SIRT5 of claim 1.
3. A recombinant expression vector comprising the DNA fragment of claim 2.
4. The recombinant expression vector of claim 3, wherein the recombinant expression vector is a lentiviral vector.
5. A host cell comprising the recombinant expression vector of claim 3 or 4.
6. The host cell of claim 4, wherein the host cell is a HepG2 cell.
7. Use of the circular RNA SIRT5 of claim 1, the DNA fragment of claim 2, the recombinant expression vector of any one of claims 3 to 4 or the host cell of any one of claims 5 to 6 in the preparation of a product for the diagnosis, treatment or monitoring of non-alcoholic fatty liver disease.
8. Use according to claim 7, wherein the product is a reagent, kit, medicament or device.
9. A medicament for treating non-alcoholic fatty liver disease, comprising the cyclic RNA SIRT5 of claim 1, the DNA fragment of claim 2, the recombinant expression vector of any one of claims 3 to 4, or the host cell of any one of claims 5 to 6, and a pharmaceutically acceptable excipient.
10. Use of the circular RNA SIRT5 of claim 1, the DNA fragment of claim 2, the recombinant expression vector of any one of claims 3 to 4, or the host cell of any one of claims 5 to 6 in the preparation of a product for inhibiting the expression of hsa-miR-150-5P or increasing the expression of a SIRT5 protein.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210305595.6A CN114606235B (en) | 2022-03-25 | 2022-03-25 | Cyclic RNA SIRT5 and application thereof in diagnosis and treatment of non-alcoholic fatty liver disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210305595.6A CN114606235B (en) | 2022-03-25 | 2022-03-25 | Cyclic RNA SIRT5 and application thereof in diagnosis and treatment of non-alcoholic fatty liver disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114606235A CN114606235A (en) | 2022-06-10 |
| CN114606235B true CN114606235B (en) | 2023-04-07 |
Family
ID=81866235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210305595.6A Active CN114606235B (en) | 2022-03-25 | 2022-03-25 | Cyclic RNA SIRT5 and application thereof in diagnosis and treatment of non-alcoholic fatty liver disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114606235B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104010651A (en) * | 2011-09-07 | 2014-08-27 | 康奈尔大学 | METHODS FOR TREATMENT OF CANCER BY TARGETING Sirt5 |
| CN107988228A (en) * | 2010-05-03 | 2018-05-04 | 库尔纳公司 | Sirtuin (SIRT) relevant disease is treated by suppressing the natural antisense transcript of Sirtuin (SIRT) |
| CA3125511A1 (en) * | 2019-02-08 | 2020-08-13 | Curevac Ag | Coding rna administered into the suprachoroidal space in the treatment of ophthalmic diseases |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019210033A1 (en) * | 2018-04-25 | 2019-10-31 | Stc Unm | Circular rnas for the diagnosis and treatment of brain disorders |
-
2022
- 2022-03-25 CN CN202210305595.6A patent/CN114606235B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107988228A (en) * | 2010-05-03 | 2018-05-04 | 库尔纳公司 | Sirtuin (SIRT) relevant disease is treated by suppressing the natural antisense transcript of Sirtuin (SIRT) |
| CN104010651A (en) * | 2011-09-07 | 2014-08-27 | 康奈尔大学 | METHODS FOR TREATMENT OF CANCER BY TARGETING Sirt5 |
| CA3125511A1 (en) * | 2019-02-08 | 2020-08-13 | Curevac Ag | Coding rna administered into the suprachoroidal space in the treatment of ophthalmic diseases |
Non-Patent Citations (7)
| Title |
|---|
| Bello JH等.Homo sapiens sirtuin 5 (SIRT5), transcript variant 26, non-coding RNA.《GenBank Database》.2022,Accession No.NR_164856.1. * |
| Bin Shang 等.Circ-Klhl8 overexpression increased the therapeutic effect of EPCs in diabetic wound healing via the miR-212-3p/SIRT5 axis.《Journal of diabetes and its complications》.2021,全文. * |
| Daofeng Zheng等.SIRT5 alleviates hepatic ischemia and reperfusion injury by diminishing oxidative stress and inflammation via elevating SOD1 and IDH2 expression.《Experimental cell research》.2022,全文. * |
| Rybak等.hsa_circ_0130765.《circBase》.2015,chr6:13579003. * |
| Xiao-Ou Zhang等.hsa_circ_17421.《circRNADb》.2014,chr6:13579682-13584457. * |
| 刘旭庆等.环状RNA的产生、研究方法及功能.《遗传》.2019,第469-485页. * |
| 曹山虎 ; 何佳丽 ; 董丽华 ; .M2型丙酮酸激酶的功能及调节.中国细胞生物学学报.2020,(08),第122-129页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114606235A (en) | 2022-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Abdollahi et al. | Dapagliflozin exerts anti-inflammatory effects via inhibition of LPS-induced TLR-4 overexpression and NF-κB activation in human endothelial cells and differentiated macrophages | |
| Jayasuriya et al. | Role of Nrf2 in MALAT1/HIF-1α loop on the regulation of angiogenesis in diabetic foot ulcer | |
| Hu et al. | The alterations of mitochondrial DNA in coronary heart disease | |
| Hao et al. | The role of microRNA-1 targeting of MAPK3 in myocardial ischemia-reperfusion injury in rats undergoing sevoflurane preconditioning via the PI3K/Akt pathway | |
| US20190153446A1 (en) | Mir-149-3p and method for treating metabolic disease using the same | |
| Chen et al. | LncRNA HULC alleviates HUVEC inflammation and improves angiogenesis after myocardial infarction through down-regulating miR-29b. | |
| Zhu et al. | Long noncoding Mirt2 reduces apoptosis to alleviate myocardial infarction through regulation of the miR-764/PDK1 axis | |
| Yuan et al. | Effects of microRNA-208a on inflammation and oxidative stress in ketamine-induced cardiotoxicity through Notch/NF-κB signal pathways by CHD9 | |
| Liu et al. | Imipramine activates FAM3A-FOXA2-CPT2 pathway to ameliorate hepatic steatosis | |
| Wei et al. | MiR-142-3p inhibits adipogenic differentiation and autophagy in obesity through targeting KLF9 | |
| Hu et al. | Ginsenoside Rd enhances blood-brain barrier integrity after cerebral ischemia/reperfusion by alleviating endothelial cells ferroptosis via activation of NRG1/ErbB4-mediated PI3K/Akt/mTOR signaling pathway | |
| Yu et al. | miR-141-3p protects against blood–brain barrier disruption and brain injury after intracerebral hemorrhage by targeting ZEB2 | |
| CN114606235B (en) | Cyclic RNA SIRT5 and application thereof in diagnosis and treatment of non-alcoholic fatty liver disease | |
| Fan et al. | Ginsenoside Rh2 attenuates myocardial ischaemia‑reperfusion injury by regulating the Nrf2/HO‑1/NLRP3 signalling pathway | |
| Meng et al. | Inhibition of Serum-and Glucocorticoid-Regulated Protein Kinase-1 Aggravates Imiquimod-Induced Psoriatic Dermatitis and Enhances Proinflammatory Cytokine Expression through the NF-kB Pathway | |
| Xu et al. | Kukoamine A activates Akt/GSK-3β signaling pathway to inhibit oxidative stress and relieve myocardial ischemia-reperfusion injury | |
| CN109793749B (en) | Application of miR-145-3p in preparation of cell apoptosis and autophagy enhancer | |
| TWI421084B (en) | A new use of microrna let-7g | |
| Agnihotri et al. | Targeting TNF-α-induced expression of TTR and RAGE in rheumatoid arthritis: Apigenin's mediated therapeutic approach | |
| Xue et al. | miR-485 regulates Th17 generation and pathogenesis in experimental autoimmune encephalomyelitis through targeting STAT3 | |
| Li et al. | Protecting against ferroptosis in hyperuricemic nephropathy: The potential of ferrostatin-1 and its inhibitory effect on URAT1 | |
| CN109943622B (en) | Medical application of nitrosoglutathione reductase | |
| Luo et al. | Inhibition of miR-423-5p exerts neuroprotective effects in an experimental rat model of cerebral ischemia/reperfusion injury | |
| Xuan et al. | Huagan tongluo Fang improves liver fibrosis via down-regulating miR-184 and up-regulating FOXO1 to inhibit Th17 cell differentiation | |
| CN115279411B (en) | Application of EphB4 as target in screening of insulin sensitivity increasing drugs or models |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |